Celularity (CELU) EBIT Margin (2020 - 2025)
Celularity's (CELU) quarterly EBIT Margin came in at 537.48% in Q4 2025, up 81136.0% year-over-year from N/an in Q4 2024, and down 120.16% quarter-over-quarter from 244.13% in Q3 2025.
Powered by 
Analysis
Celularity (CELU) EBIT Margin (2020 - 2025) Analysis & Trends
Celularity (CELU) has reported EBIT Margin for 6 consecutive years, with 537.48% the latest figure, recorded in Q4 2025.
- On a quarterly basis, EBIT Margin rose 81136.0% year-over-year to 537.48% in Q4 2025; TTM through Dec 2025 was 230.92%, a 12661.0% decrease from a year earlier, with the FY2025 full-year figure at 230.92%, down 16017.0% from the prior year.
- EBIT Margin was 537.48% for Q4 2025 at Celularity, down from 244.13% in the prior quarter.
- Over five years, EBIT Margin peaked at 423.47% in Q4 2022 and troughed at 2621.66% in Q3 2023.
- A 5-year average of 620.57% and a median of 260.35% in 2025 frame the typical range for EBIT Margin.
- Across the five-year window, EBIT Margin plunged 248512 bps in 2023 and surged 249766 bps in 2024, its largest moves.
- Over 5 years, EBIT Margin stood at 307.89% in 2021, then surged by 238 bps to 423.47% in 2022, then tumbled by 74 bps to 109.93% in 2023, then tumbled by 1327 bps to 1348.84% in 2024, then soared by 60 bps to 537.48% in 2025.
- The last three EBIT Margin figures came in at 537.48% (Q4 2025), 244.13% (Q3 2025), and 276.57% (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn | 49.00% |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | -1,151.84% |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.36 Bn | 55.72 Mn | -52.26% |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn | 14.89% |
| 5 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | -893.73% |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - | -25,827.14% |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | 41.18% |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | 3.31% |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | 0.56% |
| 10 | Celularity | 36.35 Mn | 30.17 Mn | -3.27 Mn | -537.48% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -537.48% |
| Sep 30, 2025 | -244.13% |
| Jun 30, 2025 | -276.57% |
| Mar 31, 2025 | -91.77% |
| Dec 31, 2024 | -1,348.84% |
| Sep 30, 2024 | -124.00% |
| Jun 30, 2024 | -84.01% |
| Mar 31, 2024 | -50.24% |
| Dec 31, 2023 | 109.93% |
| Sep 30, 2023 | -2,621.66% |
| Jun 30, 2023 | -1,445.75% |
| Mar 31, 2023 | -1,623.13% |
| Dec 31, 2022 | 423.47% |
| Sep 30, 2022 | -136.54% |
| Jun 30, 2022 | 110.57% |
| Mar 31, 2022 | -701.16% |
| Dec 31, 2021 | -307.89% |
| Sep 30, 2021 | 102.60% |
| Jun 30, 2021 | -1,895.87% |
| Mar 31, 2021 | -1,668.98% |